Atea Pharmaceuticals (AVIR) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 1 Phase 1[2].
Trial NCT06868264[4] evaluates Bemnifosbuvir-Ruzasvir (BEM/RZR) in HEPATITIS C VIRUS CHRONIC INFECTION with a target enrollment of 880 participants. Trial NCT07037277[5] evaluates Bemnifosbuvir-Ruzasvir in HEPATITIS C VIRUS CHRONIC INFECTION with a target enrollment of 880 participants.
AVIR has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].